CAP-CMV´s active immunogenic ingredient is Dense Bodies, produced in human CAP cells. Dense Bodies carry the most complete set of antigens and generate efficient B-cell and T-cell responses.

CAP-CMV GmbH is a venture capital backed vaccine development company founded in 2013. CAP-CMV´s lead compound is a preclinical stage vaccine for prevention of human cytomegalovirus related diseases. The active immunogenic ingredient is Dense Bodies, produced in human CAP cells and carrying the most complete set of antigens: PP65, pentamer complex (gpUL128-131), gB, gH.

Today hCMV is the major cause for seriously handicapped newborns and a major cause for serious adverse events during transplantation surgeries. Annual cost to healthcare systems in the US alone amount to above 4 billion USD. Currently there is still no vaccine available. The worldwide market potential is comparable to that of HPV vaccines. CAP-CMV´s candidate has been shown to trigger efficient T cell and B cell responses in animal models.